Key facts
- Koru Pharma’s last known valuation is $93.7M (Apr 2026).
- It has raised $25.8M; the latest was Secondary Transaction - Private ($17.7M) in Apr 2026.
- Notable investors include IMM Investment, Kolon Investment, Axis Investment, LYFE Capital, DSC Investment — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Koru Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Koru Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Koru Pharma
Operator of a pharmaceutical company specializing in medical aesthetic products for anti-aging and skin rejuvenation. The company develops and manufactures cosmetological services including anesthetics, mesotherapy, facial masks, body fillers, cosmeceutical, helping maintain the beauty, youth and health of people.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2016
- Employees
- 61
- Website
- korupharma.co.kr/
- Ownership
- Privately Held (backing)
Koru Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Koru Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Koru Pharma in its N-PORT filings yet. We sweep new filings monthly.